Abstract
Diagnostic Performance of Axillary Ultrasound in Breast Cancer
Highlights
Lymph node status is one of the most important prognostic factors in patients with invasive breast cancer [1]
Until 2011, axillary lymphadenectomy had been the standard treatment in breast cancer patients with metastases on Sentinel Lymph Node Biopsy (SLNB) [3,4]
These findings led to the questioning of current recommendations that all suspicious lymph nodes on axillary ultrasound scanning in patients who will be subjected to neoadjuvant chemotherapy should be biopsied [14]
Summary
Lymph node status is one of the most important prognostic factors in patients with invasive breast cancer [1]. Until 2011, axillary lymphadenectomy had been the standard treatment in breast cancer patients with metastases on SLNB [3,4]. SLNB after neoadjuvant chemotherapy in clinically axillary negative patients is recommended by current guidelines [7,8,9]. Studies show that neoadjuvant chemotherapy may eradicate axillary nodal disease at the time of presentation [10,11,12,13]. These findings led to the questioning of current recommendations that all suspicious lymph nodes on axillary ultrasound scanning in patients who will be subjected to neoadjuvant chemotherapy should be biopsied [14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
